logo
  

GD Awarded $42 Mln To Support US Army Medical Research And Development Programs

General Dynamics Information Technology, a business unit of General Dynamics (GD), said it was awarded a $41.8 million task order by the U.S. Army Medical Research Materiel Command to provide support services for vaccine, drug and medical device development programs to the U.S. Army Medical Materiel Development Activity.

This task order was awarded under the TRICARE Evaluation, Analysis and Management Support or TEAMS contract vehicle and has a term of four years and seven months. USAMMDA is the U.S. Department of Defense's advanced medical materiel development activity for products designed to protect and preserve the lives of service members.

General Dynamics said it will deliver a wide range of services to help the USAMMDA guide new medical technologies through the U.S. Food and Drug Administration regulatory and certification process and develop plans to bring these new products into service.

General Dynamics said it has partnered with Tunnell Government Services Inc., a life sciences technical services consulting leader in biotechnology, medical devices and pharmaceutical product development, on this contract. The companies will provide health, medical research, clinical trial and regulatory expertise as well as information, acquisition and program management support services.

General Dynamics anticipates hiring more than 30 new employees to perform this work at Fort Detrick in Frederick, Md. The company has supported the USAMMDA for four years under a task order issued by the U.S. Army Medical Research Acquisition Activity.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Philip Morris International Inc. (PM) reported Tuesday that net earnings attributable to PMI for the quarter grew to $2.15 billion or $1.38 per share from $2.00 billion or $1.28 per share in the prior-year quarter. Excluded items, adjusted earnings for the quarter were $1.50 per share, compared to... Novartis AG's shares were gaining more than 4 percent in Switzerland and more than 5 percent in pre-market activity on the NYSE after the Swiss drug major reported Tuesday higher first-quarter profit, above market estimates, with strong sales growth. The company also raised its fiscal 2024 outlook for growth in sales and core operating income. Primal Kitchen is recalling around 2,060 cases of three code dates of Primal Kitchen Avocado Oil as the glass may be prone to breakage, causing the product to spill, the U.S. Food and Drug Administration noted. The recall involves 750mL Primal Kitchen Avocado Oil with an individual package UPC of 8-5523200719-4.

First quarter growth data from China gained the maximum focus this week as trends in the massive emerging economy impact its trading partners. Elsewhere, the IMF released its latest global macroeconomic projections. Read our story to find out why comments from the Fed Chair Powell damped rate cut expectations. Meanwhile, there was some survey data that kindled hopes of a recovery in manufacturing. In the U.K., inflation data for March revealed some confusing trends.

View More Videos
Follow RTT